DNA repair and synthetic lethality

International Journal of Oral Science

Volumn 3, Issue 4, 2011, Pages 176-179

  Guo, Gongshe ^a   Zhang, Fengmei ^a   Gao, Ruijie ^b   Delsite, Robert ^c   Feng, Zhihui ^a,c   Powell, Simon N ^c  

^a SHANDONG UNIVERSITY   (China)

^b WEIFANG PEOPLE'S HOSPITAL   (China)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BRCA; DNA repair; homologous recombination; Rad52; synthetic lethality

Indexed keywords

ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RAD52 PROTEIN;

ANIMAL; BREAST TUMOR; DNA REPAIR; DRUG ANTAGONISM; DRUG EFFECT; GENE; GENE EXPRESSION REGULATION; GENETIC RECOMBINATION; GENETICS; HUMAN; LETHAL GENE; MUTAGENESIS; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA REPAIR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; GENES, LETHAL; GENES, TUMOR SUPPRESSOR; HUMANS; MUTAGENESIS; POLY(ADP-RIBOSE) POLYMERASES; RAD52 DNA REPAIR AND RECOMBINATION PROTEIN; RECOMBINATION, GENETIC;

EID: 80055081013     PISSN: 16742818     EISSN: 20493169     Source Type: Journal    
DOI: 10.4248/IJOS11064     Document Type: Review

References (25)

1. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-698. (Pubitemid 41486362)
2. Nijman SM. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett 2011; 585: 1-6.
3. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921. (Pubitemid 40559006)
4. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005; 434: 913-917. (Pubitemid 40559005)
5. Helleday T. Homologous recombination in cancer develop-ment, treatment and development of drug resistance. Carci-nogenesis 2010; 31: 955-960.
6. Evers B, Helleday T, Jonkers J. Targeting homologous recombination repair defects in cancer. Trends Pharmacol Sci 2010; 31: 372-380.
7. Amir E, Seruga B, Serrano R, Ocana A. Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treat Rev 2010; 36: 557-565.
8. Satoh MS, Lindahl T. Role of poly (ADP-ribose) formation in DNA repair. Nature 1992; 356: 356-358.
9. Strom CE, Johansson F, Uhlen M, et al. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res 2011; 39: 3166-3175.
10. Paques F, Haber JE. Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol Mol Biol Rev 1999; 63: 349-404. (Pubitemid 29264976)
11. Liu J, Heyer WD. Who's who in human recombination: BRCA2 and RAD52. Proc Natl Acad Sci USA 2011; 108: 441-442.
12. Fujimori A, Tachiiri S, Sonoda E, et al. Rad52 partially substitutes for the Rad51 paralog XRCC3 in maintaining chromosomal integrity in vertebrate cells. EMBO J 2001; 20: 5513-5520. (Pubitemid 32959471)
13. Feng Z, Scott SP, Bussen W, et al. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci USA 2011; 108: 686-691.
14. James CR, Quinn JE, Mullan PB, Johnston PG, Harkin DP. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 2007; 12: 142-150.
15. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-819. (Pubitemid 39331153)
16. Tomlinson GE, Chen TT, Stastny VA, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 1998; 58: 3237-3242. (Pubitemid 28371058)
17. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008; 98: 523-528. (Pubitemid 351214533)
18. Koniaras K, Cuddihy AR, Christopoulos H, Hogg A, O'Connell MJ. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 2001; 20: 7453-7463. (Pubitemid 33086904)
19. Chen CC, Kennedy RD, Sidi S, Look AT, D'Andrea A. CHK1 inhibition as a strategy for targeting Fanconi anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 2009; 8: 24.
20. Leijen S, Beijnen JH, Schellens JH. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol 2010; 5: 186-191.
21. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004; 64: 9152-9159. (Pubitemid 39665530)
22. Alabert C, Bianco JN, Pasero P. Differential regulation of homologous recombination at DNA breaks and replication forks by the Mrc1 branch of the S-phase checkpoint. EMBO J 2009; 28: 1131-1141.
23. Sorensen CS, Hansen LT, Dziegielewski J, et al. The cell-cycle checkpoint kinase Chk1 is required for mam-malian homologous recombination repair. Nat Cell Biol 2005; 7: 195-201. (Pubitemid 40268135)
24. Powell SN, DeFrank JS, Connell P, et al. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 1995; 55: 1643-1648.
25. Shi W, Feng Z, Zhang J, et al. The role of RPA2 phosphorylation in homologous recombination in response to replication arrest. Carcinogenesis 2010; 31: 994-1002.